Q-omics provides the consensus-scored RAD21 profile across patient tissues and cancer cell-line models. RAD21 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAD21 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RAD21 protein abundance shows 29,145 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where RAD21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD21 survival associations across molecular data types. RAD21 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD21 RNA expression–survival associations across cancer types. High RAD21 expression shows unfavorable associations in UVM, LIHC, MESO, ACC and SARC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAD21 RNA expression.
This table summarizes RAD21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAD21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD21 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, BRCA and BLCA. The HNSC box plot shows higher RAD21 RNA expression in tumor versus normal tissue (log2 FC = +1.593, t-test p < 0.001).
This table shows molecular features associated with RAD21 in patient tissues and cancer cell lines. In patient samples, RAD21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
